Friday, May 10, 2019

Next-gen Pharma is expensive, and insurance is complicated

Even though this article is not related to ADCs it is an interesting look at how insurance companies are grappling with the very real issue of treatments which can cost up to $4M per patient.

This article is particularly interesting in that they talk with insurance companies who are grappling with how to pay for all of this.  There are some ideas about installment plans, but that is complicated by things like:  What happens if the therapy stops working?  Would people continue to pay for an ineffective treatment?  Or what would happen if a person got a new job and therefore a new insurance company?  Would that new insurance company be liable for continuing payment on the old plan?

This author gives us an interesting look at the world behind the science, behind the patients, and down in the nitty gritty of the reality that curing cancer costs money, and the buck has to stop somewhere.

There is another article written by one of my favorite authors - Mark Terry at Biospace - where he interviews the authors of a review paper covering the same topic.
or the source review article can be found at:

What do you think?  Is there a point where a treatments cost should be factored in as an approval factor?  Is 10X higher cost acceptable for a 5% +/- 4% treatment option?

No comments:

Post a Comment